Iris Publishers - Current Trends in Clinical & Medical Sciences (CTCMS)

 Ongoing COVID-19 Clinical Trials: A Pharmacological Perspective on Pneumonia

Authored by Prof. Dr. Amani E Khalifa


Introduction

Coronavirus disease 2019; the current pandemic, is a newly emerged viral pneumonia that was named COVID-19 by the WHO on February 11th, 2020 [1]. The causative agent of this viral pneumonia is the SARS-CoV-2 which was found to be closely similar to SARS-CoV with about 80% sequence identity [2]. Although the pathogenesis of COVID-19 disease including the mechanisms of antigen presentation is poorly understood, the high similarity between SARS-CoV-2 and SARS-CoV was reflected in the clinical course of the disease where the virus typically attacks the lungs in certain vulnerable populations in three phases; viral replication, immune hyper-reactivity, and pulmonary destruction [3].

Clinical studies of COVID-19 disease

The database registry of “ClinicalTrials.gov” run by the United States National Library of Medicine at the National Institutes of Health includes all privately and publically funded clinical studies conducted in 211 countries around the world. Observational and interventional studies from Egypt (148 studies) and the rest of the world (4019 studies) are taking place [4]. Among such running clinical trials is our team’s principal investigation of the roles of Egyptian pharmacists in combating this disease that is available at: https://clinicaltrials.gov/ct2/show/NCT04374513

Specifically, “Clinicaltrials.gov” database registry classified the overall listed clinical studies related to COVID-19 into many categories according to the targeted condition. Three categories are most prominent; one major category targeting the COVID-19 disease condition in general including mild, moderate and/or severe disease with or without evidence of pneumonia, another category of clinical studies targeting confirmed COVID-19 pneumonia, and a third category targeting COVID-19 associated ARDS, with some overlap that might exist among these categories. Among the updated total of 4019 studies on COVID-19 generally, the refined search strategy yielded only 747 on pneumonia in COVID-19 [5].

From a pharmacological point of view, it is important to focus on the second category of clinical studies targeting COVID-19 pneumonia rather than COVID-19 associated ARDS or the broad COVID-19 disease categories for many reasons. First, the majority of COVID-19 patients exhibit mild to moderate symptoms, and only 15% of patients progress to severe pneumonia cases within which about 5% eventually develop ARDS, septic shock, and/or multiple organ failure [3,6]. So, the disease can be tolerated by most patients with a positive outcome of viral load reduction/ clearance, followed by receding of inflammation and in this population, the benefit/risk ratio of any pharmacological intervention may not be ethically justified and may also negatively affect their otherwise capable immune system function. The category of clinical trials targeting the COVID-19 disease condition in general including mild, moderate, and/or severe disease, therefore may expose many cases to unneeded and unknown risk due to the medications’ side effects/toxicities in this novel disease. Also, the same pharmacological interventions may not be appropriate for all levels of disease severity given the reported multistage pathophysiology of CoVs discussed earlier. On the other hand, patients experiencing ARDS develop overwhelming lung hyper-inflammatory cytokine storm and acute respiratory failure; a critical and late condition in the course of COVID-19 disease that might not allow for a completely successful intervention. Therefore, in clinical trials targeting COVID-19 associated ARDS, reaching a safe and effective pharmacotherapy would be utterly difficult. Besides, treatment before the onset of ARDS could be a wise decision since the overall prognosis of ARDS is poor, with mortality rates of approximately 40% [7], and even if patients survive, they might face other life-long physical and psychological consequences after exhausting their economic and national healthcare systems.

It is also important to focus on the second category of clinical studies targeting COVID-19 pneumonia rather than COVID-19 associated ARDS or the broad COVID-19 disease category since the available clinical data indicates that the majority of COVID-19 patients had pneumonia while only small percentage had ARDS. In a Chinese cohort of 1,099 patients with COVID-19, 93.6% were hospitalized, 91.1% had pneumonia, 5.3% were admitted to the ICU, 3.4% had ARDS and only 0.5% had acute kidney injury [8]. In addition, a retrospective study that included 357 patients with ARDS who chronic kidney disease or acute kidney injury before ARDS presentation did not have reported that pneumonia was the cause of ARDS in 83% of patients [9]. Therefore, safe and effective treatment for COVID-19 pneumonia is necessary, particularly if targeted to the cases with potential bad prognosis whose immune system could not otherwise overcome such illness without intervention (Figure 1).

To read more about this article: https://irispublishers.com/ctcms/fulltext/ongoing-covid-clinical-trials-a-pharmacological-perspective-on-pneumonia.ID.000533.php

Indexing List of Iris Publishers: https://medium.com/@irispublishers/what-is-the-indexing-list-of-iris-publishers-4ace353e4eee

Iris publishers google scholar citations: https://scholar.google.co.in/scholar?hl=en&as_sdt=0%2C5&q=irispublishers&btnG=

Comments

Post a Comment

Popular posts from this blog

Iris Publishers - Current Trends in Clinical & Medical Sciences (CTCMS)

Image
Turning Back the Clock: The Effect of the COVID-19 Response in Sub-Saharan Africa and Other Low- Income Countries Authored by Sanghvi Reema Introduction The COVID-19 pandemic has affected everyone across the world, either through the disease itself or with our response to the disease as healthcare professionals, for the better part of a year. In the matter of a few months, it managed to spread from its little corner of the world to a true pandemic. In response to this global pandemic many affluent nations have instituted lockdown procedures to protect their population, a practice that has been adopted by many low to low- middle income countries (LMICs) as well. Unfortunately, this pandemic does not take place in a vacuum, and individuals can have more than one condition with resultant needs outside their homes. This becomes readily apparent when considering someone receiving medical treatment for a disease such as HIV or TB, who may struggle keeping their treatment appointments. I...
Read more

Iris Publishers - Current Trends in Clinical & Medical Sciences (CTCMS)

Image
Pharmacoeconomic Evaluation of Novel Oral Anticoagulants in Patients with Cardiovascular Diseases: A Systematic Review Authored by Ahmed Ibrahim Nouri Introduction For decades, the oral anticoagulant warfarin remained the gold standard of medical management for many cardiovascular diseases and main pharmacological agents for the prophylaxis of venous thromboembolism [1]. Among these cardiovascular patients, the vitamin K antagonists are especially beneficial to patients with venous thromboembolism and for the prevention of stroke. In terms of clinical consideration, warfarin displays several limitations and disadvantages. The narrow therapeutic window and vast drugdrug and drug-food interactions properties of warfarin render it clinically difficult to use [2]. Precise dose adjustment and frequent dose monitoring are of utmost importance because inappropriate dose can lead to many adverse clinical events. Warfarin over-dose will increase the risk of serious bleeding while under-dose ...
Read more